---
title: "Weekly Recap | Flex +7.46%, Innovation Day pivots to AI infrastructure"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305534738.md"
description: "Flex (FLEX) rose 7.46% this week to $74.98, outpacing the S&P 500’s 2.51% gain by about 4.95 percentage points. The stock opened higher on Monday, pushed as high as $82.70 on Wednesday, and then gave back much of the gains on Thursday and Friday, closing near the lower end of the 72.04-78.24 Friday range. Weekly amplitude hit 14.62%, and average daily volume ran roughly 49% above the recent median, pointing to unusually active trading."
datetime: "2026-11-14T06:23:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305534738.md)
  - [en](https://longbridge.com/en/news/305534738.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305534738.md)
generator: "portal-rs"
---

# Weekly Recap | Flex +7.46%, Innovation Day pivots to AI infrastructure

## The Week

Flex (FLEX) rose 7.46% this week to $74.98, outpacing the S&P 500’s 2.51% gain by about 4.95 percentage points. The stock opened higher on Monday, pushed as high as $82.70 on Wednesday, and then gave back much of the gains on Thursday and Friday, closing near the lower end of the 72.04-78.24 Friday range. Weekly amplitude hit 14.62%, and average daily volume ran roughly 49% above the recent median, pointing to unusually active trading.

## Key Events

The standout corporate event was the 2026 Innovation Day on 10 November, where Flex presented its reshaping around AI infrastructure. That became the main narrative behind the week’s price swings. On 11 November, the stock surged nearly 9% intraday, matching renewed attention after the event. On 13 November, a commentary piece revisited whether Flex remains cheap given its AI-infrastructure repositioning, feeding pre-market volatility on Friday. No material filings or regulatory updates appeared during the week.

## Analyst Ratings

Eleven firms cover Flex, with 8 buy and 3 overweight ratings; there are no hold, underweight, or sell ratings. The consensus is strong buy, and the consensus target price is $151.4, roughly 102% above the spot price of $74.98. Target prices range from $128 to $176, showing a wide spread. Within the electronic equipment and services industry, Flex ranks 11th out of 67 firms, above the industry median of 3.

## The Week Ahead

Next week, the New York Fed manufacturing index lands on 16 November, followed on 17 November by retail sales, industrial production, and the NAHB housing market index. These prints could shift risk appetite across tech hardware. For Flex itself, third-quarter fiscal 2027 results are scheduled for 27 January 2027, with consensus estimates at $1.04 EPS and $9.085 billion revenue, up about 51% and 33% year on year.

## In Short

Flex had a rally-and-fade week. The sell-side is clearly positive, with a consensus target far above spot, while the wide target range and mid-tier industry ranking leave room for debate. Valuation sits at about 26.7x P/E and 4.77x P/B, both on the higher side. The latest session’s flows were mixed: large and medium orders were net buyers, while small orders were net sellers. The key question is whether AI-infrastructure momentum can justify current multiples, and how next week’s macro data resets sentiment for hardware names.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [FLEX.US](https://longbridge.com/en/quote/FLEX.US.md)

## Related News & Research

- [Flex Subsidiary Axiom Signs $4.57 Billion Credit Agreement Ahead of Spinoff](https://longbridge.com/en/news/305871494.md)
- [How Investors Are Reacting To Flex (FLEX) Boosting 2027 Sales Outlook On AI Infrastructure Momentum](https://longbridge.com/en/news/294605039.md)
- [Space Exploration Technologies (SPCX) Gets A New Hiring Twist As Musk Eyes Top AI Talent](https://longbridge.com/en/news/306383945.md)
- [Salesforce (CRM) Chosen To Lead U.S. Backed Super Intelligence Export Group](https://longbridge.com/en/news/306383121.md)
- [CAPR: FDA issued a CRL for Deramiocel, citing insufficient evidence of effectiveness](https://longbridge.com/en/news/306366333.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**